Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04683744 · ClinicalTrials.gov registry record
Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation
A clinical trial, sponsored by Indiana University.
- Completed
- Registry status
- 82
- Enrollment target
NCT04683744: Completed study, sponsored by Indiana University.
NCT04683744 is a clinical trial that has completed, run by Indiana University. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04683744 has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
The rate of screening for colorectal cancer (CRC) in the U.S. remains low (under 65%), meaning that thousands of people die of colorectal cancer unnecessarily. Colorectal cancer screening tests range from more invasive and very sensitive for polyps and cancer (colonoscopy) to less invasive and less sensitive (e.g., fecal immunochemical testing (FIT)). Screening rates go up when patients consider all these tests, not just colonoscopy. Informing patients about their options for CRC screening could produce higher quality decisions, improve the match between patient preferences and tests performed, and increase uptake of CRC screening. Decision aids (DAs) are a promising tool for accomplishing this goal. Also, precision CRC prevention - providing information about an individual's specific risk for CRC - has great promise to increase uptake and improve decision making. Unfortunately, the COVID-19 pandemic is causing severe challenges to providing CRC screening and other prevention services. Health systems are trying to adapt, but these efforts have only begun and are poorly understood. Moreover, patient perceptions of disease risk and risk from COVID-19 are unknown.
Primary Outcome
Semi-structured interviews with health system leadership, providers and staff conducted every 3-4 months to discuss facilitators and barriers to implementing decision aids, provider notification, and personal risk calculation using an EHR to promote cancer screening.
Interventions
- OTHER Semi-structured interviews-Patients
- OTHER Semi-structured interviews-Health system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2023-07-31 |
What the finished NCT04683744 record still lists
NCT04683744 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Semi-structured interviews-Patients is the first listed.
NCT04683744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04683744 about?
NCT04683744 is a clinical study titled "Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation". The rate of screening for colorectal cancer (CRC) in the U.S. remains low (under 65%), meaning that thousands of people die of colorectal cancer unnecessarily. Colorectal cancer screening tests range from more invasive and very sensitive for polyps and cancer (colonoscopy) to less invasive and less ...
What is the current status of trial NCT04683744?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2021-01-11. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT04683744?
The interventions under investigation include: Semi-structured interviews-Patients (OTHER), Semi-structured interviews-Health system (OTHER).
Who is sponsoring clinical trial NCT04683744?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI